TICKERNERD
Menu
DRUGDRUGHealthcare · Biotechnology

DRUG Stock Forecast: Bright Minds Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$63

The 7 Wall Street analysts covering Bright Minds Biosciences, Inc. hold a median 12-month price target of $145 — +129.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$619.9M
Ticker Nerd rank
47 / 100
Median analyst target
$145
Analysts covering
7
Revenue$0.0
Operating income−$11.4M
Net income−$2.4M
Free cash flow−$8.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

DRUG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bright Minds Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
78
Revisions
71
Value
68
Momentum
63
Size
51
Issuance
32
Growth
25
Volatility
23
Accruals
23

Quality (78): The business earns solid, repeatable profits on what it owns.

Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DRUG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRUG, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $144Median $145High $220

The green dot is the last close — the median target sits +129.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026HC Wainwright & Co.ReiteratesBuy$145
17 Aug 2026BTIGReiteratesBuy$147
1 June 2026HC Wainwright & Co.ReiteratesBuy—
1 June 2026HC Wainwright & Co.ReiteratesBuy$145
20 May 2026Piper SandlerMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
30 Mar 2026BTIGReiteratesBuy—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
17 Feb 2026BTIGMaintainsBuy—
7 Jan 2026BTIGMaintainsBuy—
6 Jan 2026BTIGMaintainsBuy—
2 Jan 2026Chardan CapitalMaintainsBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
8 Sept 2025BTIGInitiatesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
2 July 2025Cantor FitzgeraldAssumesOverweight—
21 May 2025Chardan CapitalMaintainsBuy—
13 May 2025TD CowenInitiatesBuy—
7 May 2025Chardan CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRUG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DRUG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Bright Minds Biosciences, Inc. (DRUG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
2.8×

Cheaper than 35% of US stocks

EV / EBITDA
−16.2×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−13.6%

Higher than 34% of US stocks

Return on assets
−13.5%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bright Minds Biosciences, Inc. (DRUG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bright Minds Biosciences, Inc. has a market value of $619.9M and an enterprise value of $227.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$24.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$24.7M.

  • Shares outstanding: 9.8M.

  • Trailing P/E: 0.3×; forward P/E: −10.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bright Minds Biosciences, Inc. employs 26 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

DRUG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRUGBright Minds Biosciences, Inc.$619.9M
47
CRMDCorMedix, Inc.$613.0M
60
STTKShattuck Labs, Inc.$622.3M
73
ALTAltimmune, Inc.$635.5M
25
OABIOmniAb, Inc.$591.7M
95
BLSMBlossomhill Therapeutics, Inc.$639.2M
1
ASMBAssembly Biosciences, Inc.$590.6M
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bright Minds Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DRUG news & analysis

Bright Minds Biosciences to Present at Upcoming Conferences

GlobeNewsWire · 4 Sept 2026positive

Bright Minds Biosciences announced it will present at upcoming conferences, including the Cantor Global Healthcare Conference 2026 on September 9, 2026, and an H.C. event. The company develops 5-HT2 agonists for treating drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders.

Why it matters — Conference presentations give Bright Minds the opportunity to raise visibility with the investment and healthcare communities regarding its pipeline of CNS-focused therapies.

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 27 Aug 2026positive

Zacks Investment Research published an article asking whether Bright Minds Biosciences Inc. (DRUG) could be a strong momentum stock pick, examining its characteristics as a candidate for momentum investors.

Why it matters — The article highlights DRUG as a potential momentum opportunity, which could draw attention from investors focused on price and earnings trends.

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

Zacks Investment Research · 26 Aug 2026positive

Zacks reports that Wall Street analysts' average price target for Bright Minds Biosciences (DRUG) implies a potential upside of about 97%. The article notes this metric's reliability is questionable but highlights a positive trend in earnings estimate revisions.

Why it matters — A DRUG watcher would care because the piece draws attention to analyst price targets implying significant upside potential and a favorable earnings-estimate revision trend for the company.

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research reports that analysts' mean price target for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock, while noting the metric has not proven highly effective historically. The report adds that strong agreement among analysts in raising earnings estimates indicates an upside in the stock.

Why it matters — Analysts' upward earnings estimate revisions and a consensus price target above the current price are signals DRUG shareholders would watch for a potential rise in the stock.

Vistagen Appoints Douglas J. Williamson to its Board of Directors

GlobeNewsWire · 31 July 2026neutral

Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience product candidates called pherines.

Why it matters — While this news concerns Vistagen, not Bright Minds Biosciences, a DRUG watcher may note board appointments at peer neuroscience companies as signals of industry direction or governance trends in the space.

FAQ

Frequently asked questions about DRUG stock

What is the DRUG stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Bright Minds Biosciences, Inc. have a median 12-month price target of $145, with estimates ranging from $144 to $220. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRUG stock a buy right now?

Of the 7 analysts covering Bright Minds Biosciences, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bright Minds Biosciences, Inc. 47 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRUG?

As at 12 Sept 2026, Bright Minds Biosciences, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (78 of 100).

Will DRUG stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +129.5% from the last close, and Ticker Nerd's factor model ranks Bright Minds Biosciences, Inc. 47 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRUG stock forecast for 2030?

No analyst covering Bright Minds Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRUG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $144 to $220 over the next 12 months.

What does Bright Minds Biosciences, Inc. do?

Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders.

What is the latest news on DRUG?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Bright Minds Biosciences to Present at Upcoming Conferences". Bright Minds Biosciences announced it will present at upcoming conferences, including the Cantor Global Healthcare Conference 2026 on September 9, 2026, and an H.C. event. The company develops 5-HT2 agonists for treating drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders.

Company

About Bright Minds Biosciences, Inc.

Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders. The company’s research emphasizes selective small-molecule drug candidates designed to address severe and life-altering diseases with high unmet medical need. Its current business is centered on drug discovery and development, supported by a pipeline of preclinical and clinical programs in neurology and psychiatry. Bright Minds Biosciences Inc. operates as a research-driven biotech platform focused on advancing novel therapeutics from early development toward potential clinical use.

CEO Mr. Ian McDonald · 26 employees · United States · https://brightmindsbio.com